Imidazole-Based AT₁ Receptor Ligands: Design, Synthesis and Pharmacological Evaluation

The angiotensin II type 1 (AT₁) receptor is a key component of the renin-angiotensin system (RAS) and a validated target for cardiovascular and renal disorders. Developing small molecules with defined AT₁ versus AT₂ binding profiles remains important for both therapeutic and mechanistic studies. Here, a series of novel imidazole-based compounds was synthesized and evaluated for their binding affinities toward angiotensin II type 1 (AT₁) and type 2 (AT₂) receptors. Binding studies were conducted by measuring the displacement of radiolabeled [³H]-angiotensin II ([³H]-AII) in PLC-PRF-5 human hepatoma cells for AT₁ receptors and calf cerebellum membranes for AT₂ receptors. Structure-activity relationship (SAR) analysis revealed that sulfonamide substitution significantly enhanced AT₁ receptor affinity, whereas sterically hindered derivatives and ester-containing compounds were less active. Molecular docking studies using the AT₁ receptor crystal structure (PDB: 8TH4) rationalized the observed activity trends. The most active compound showed high AT₁ affinity (Ki = 5 nM), comparable to losartan, and all compounds displayed preferential binding for AT₁ over AT₂ receptors.